






# CanAssist-Breast : Risk Stratification Test



Morphometric IHC-based test to stratify breast cancer patients based on risk of recurrence. CanAssist-Breast integrates IHC data and clinical parameters into a statistical algorithm which provides CanAssist-Breast (CAB) score that stratifies patients as “low-risk” or “high-risk” for distant recurrence over 5 years.



## Clinical Validation: Kaplan-Meier Survival Analysis





# Risk stratification independent of nodal status



## CanAssist-Breast is an independent predictor of prognosis

Multivariate Cox Model	Hazard Ratio	P-value
Age	1.47	0.16
ER	0.97	0.93
PR	1.65	0.07
Treatment modality	0.70	0.27
<b>CanAssist-Breast</b>	<b>3.44</b>	<b>&lt;0.0001</b>

## Chemotherapy Benefit for high-risk patients




**Absolute chemotherapy benefit for high-risk patients: 22%**

# CanAssist-Breast vs Competing Products


	Oncotype Dx	Mammaprint	Prosigna	Endopredict	<b>CanAssist-Breast</b>
<b>Indicated for</b>	ER+/PR+/HER2-, stage I, II, lymph node-negative (N0), and 1-3 nodes positive (N1)				ER+/PR+/HER2 - ; lymph node N0 & N1, Stage 1, 2
<b>Genes Used</b>	Primarily ER, PR, HER2 and proliferation based genes				Breast cancer metastasis pathways - invasion, stem cells, drug resistance, indicators of proliferation - tumor grade
<b>Risk-stratification</b>	>40% patients in intermediate zone	No intermediate zone	>30% patients in intermediate zone	No intermediate zone	No intermediate zone
<b>Outcome</b>	Prognostic and CT-predictive	Prognostic	Prognostic	Prognostic	Prognostic and predictive of chemotherapy benefit
<b>TAT</b>	21 days	21 days	21 days	21 days	10 days
<b>Regulatory Approvals</b>	Only CLIA certified	FDA 510(k), CE Mark	FDA 510(k), CE Mark	CE Mark	ISO 13485, CE Mark. Performed in NABL-accredited laboratory
<b>Price USD</b>	4000	4000	2200	2200	<b>Most affordable</b>

## CanAssist-Breast : looks beyond proliferation pathways


### Events in cancer progression



### 5 Biomarkers for CAB



### Signaling Pathways and biological events



Self renewal, loss of cell adhesion, migration, invasion, drug resistance, EMT/MET are key to METASTASIS

# Case Studies

## Patient 1

**Age:** 50 Years.

**Diagnosis:** HR+/HER2-/  
Grade II/node-negative IDC of breast,  
Stage 2, Ki 67: 45%

**Standard Treatment:**  
Surgery + Chemotherapy +  
Radiation Therapy + Hormonal Therapy

**CanAssist-Breast Score 7.1**

CanAssist-Breast classified her as **low-risk**  
with no added benefit of chemotherapy.

Patient's treatment planned accordingly.

## Patient 2

**Age:** 50 Years.

**Diagnosis:** HR+/HER2-/  
Grade II/node-negative IDC of breast,  
Stage 1, Ki 67: 20%

**Standard Treatment:**  
Surgery + Chemotherapy +  
Radiation Therapy + Hormonal Therapy

**CanAssist-Breast Score 20**

CanAssist-Breast classified her as **high-risk**  
and can benefit from chemotherapy.

Patient's treatment planned accordingly.

# CanAssist-Breast



## Contact Information

OncoStem Diagnostics Pvt. Ltd.  
#4, Raja Ram Mohan Roy Road,  
Aanand Tower, 2nd floor, South wing,  
Bangalore – 560027.

+91 96866 96505  
+91 80 222 400 34

[info@oncostemdiagnostics.com](mailto:info@oncostemdiagnostics.com)

[www.oncostemdiagnostics.com](http://www.oncostemdiagnostics.com)

\* OncoStem is NABL accredited for ER, PR, HER2 IHC testing.

ODPL.BD.DS.009.03